Decision on EU marketing authorisation for this population expected by September 2024
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Imfinzi also recommended for patients with mismatch repair deficient disease
_256_384.jpg)
Glenmark released Picture Post Cards on World Vitiligo Day
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
Subscribe To Our Newsletter & Stay Updated
